Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of ALD-101 adjuvant therapy in unrelated umbilical cord blood transplantation for inborn errors of metabolism
2009-017026-39Phase 3Active
- Sponsor
- Aldagen
- Start
- Oct 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, single-arm trial of ALD-101 in Congenital Metabolic Diseases, sponsored by Aldagen. Primary endpoint: Time to platelet engraftment. Started Oct 2009; status: active.
02
Drugs
ALD-101
03
Conditions
Congenital Metabolic Diseases
Beyond the preview
Go deeper on 2009-017026-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017026-39.